US stocks opened mixed, according to market data cited by ChainCatcher from Gate. At the open, the Dow Jones Industrial Average fell 0.1%, the S&P 500 rose 0.13%, and the Nasdaq gained 0.3%.
Among individual names, biotech company uniQure fell 39% after 48-month data for its Huntington’s disease gene therapy failed to reach statistical significance. Summit Therapeutics rose 19.2% after AstraZeneca had proposed a $2 billion investment in the company to jointly develop an anticancer drug.
The moves highlighted sharp divergence between the broader US equity benchmarks and select biotech stocks at the open.
US stocks opened mixed, according to Gate market data cited by ChainCatcher. The Dow Jones Industrial Average fell 0.1% at the open, while the S&P 500 rose 0.13% and the Nasdaq gained 0.3%.
In single-stock moves, biotech company uniQure dropped 39% after 48-month data for its Huntington’s disease gene therapy failed to achieve statistical significance.
Summit Therapeutics climbed 19.2% after AstraZeneca had proposed a $2 billion investment in the company to cooperate on developing an anticancer drug.
This article was originally published by Bit.Fan. For more cryptocurrency news and market insights, visit www.bit.fan. Disclaimer:
The market information, project data, and third-party content displayed on this platform are for industry information sharing only and do not constitute any form of investment advice or return commitment.
Cryptocurrency trading carries high risks. Users should fully assess their risk tolerance and make independent decisions. All profits, losses, and legal responsibilities are borne by the users themselves.
